TW202014182A - Cd73抑制劑 - Google Patents
Cd73抑制劑 Download PDFInfo
- Publication number
- TW202014182A TW202014182A TW108115143A TW108115143A TW202014182A TW 202014182 A TW202014182 A TW 202014182A TW 108115143 A TW108115143 A TW 108115143A TW 108115143 A TW108115143 A TW 108115143A TW 202014182 A TW202014182 A TW 202014182A
- Authority
- TW
- Taiwan
- Prior art keywords
- alkyl
- cycloalkyl
- aryl
- heterocycloalkyl
- heteroaryl
- Prior art date
Links
- 0 CC(C(C(C)C1=*(C)CC1)*1C(C)CC1)C1C=*CC1 Chemical compound CC(C(C(C)C1=*(C)CC1)*1C(C)CC1)C1C=*CC1 0.000 description 14
- LBUDEMPMVMSZMC-RRFJBIMHSA-N CC(C)(C)OC(N(C1CCCC1)c1c(cn[n]2[C@@H](C3)O[C@H](CO)[C@H]3O)c2nc(Cl)n1)=O Chemical compound CC(C)(C)OC(N(C1CCCC1)c1c(cn[n]2[C@@H](C3)O[C@H](CO)[C@H]3O)c2nc(Cl)n1)=O LBUDEMPMVMSZMC-RRFJBIMHSA-N 0.000 description 1
- DKUPVFKYJOTDRQ-YKTARERQSA-N CC(C)(C)OC(N(C1CCCC1)c1c(cn[n]2[C@@H]3O[C@H](CS)[C@H]4OC(C)(C)O[C@@H]34)c2nc(Cl)n1)=O Chemical compound CC(C)(C)OC(N(C1CCCC1)c1c(cn[n]2[C@@H]3O[C@H](CS)[C@H]4OC(C)(C)O[C@@H]34)c2nc(Cl)n1)=O DKUPVFKYJOTDRQ-YKTARERQSA-N 0.000 description 1
- KNIKPAXGKGKNKT-RXUYWNQFSA-N CC(CO)(OC[C@H]([C@H]([C@H]1O)O)O[C@H]1[n]1c2nc(Cl)nc(NC3CCCC3)c2cc1)P(O)(O)=O Chemical compound CC(CO)(OC[C@H]([C@H]([C@H]1O)O)O[C@H]1[n]1c2nc(Cl)nc(NC3CCCC3)c2cc1)P(O)(O)=O KNIKPAXGKGKNKT-RXUYWNQFSA-N 0.000 description 1
- HMMDUOFZSKNGOH-CDMSWCOPSA-N CC(COC)(OC[C@H]([C@H]([C@H]1O)O)O[C@H]1[n]1ncc2c1nc(C#CC1(CC1)O)nc2NC1CCCC1)P(O)(O)=O Chemical compound CC(COC)(OC[C@H]([C@H]([C@H]1O)O)O[C@H]1[n]1ncc2c1nc(C#CC1(CC1)O)nc2NC1CCCC1)P(O)(O)=O HMMDUOFZSKNGOH-CDMSWCOPSA-N 0.000 description 1
- PNFBXEASENQIGI-JQGYAOAWSA-N CC(OC[C@H]([C@H]([C@H]1O)O)O[C@H]1[n](c1n2)ncc1c(NC1CCCC1)nc2Cl)P(O)(O)=O Chemical compound CC(OC[C@H]([C@H]([C@H]1O)O)O[C@H]1[n](c1n2)ncc1c(NC1CCCC1)nc2Cl)P(O)(O)=O PNFBXEASENQIGI-JQGYAOAWSA-N 0.000 description 1
- MAELJKQPTFAWLB-JQGYAOAWSA-N CC(P(O)(O)=O)S(C[C@H]([C@H]([C@H]1O)O)O[C@H]1[n](c1n2)ncc1c(NC1CCCC1)nc2Cl)(=O)=O Chemical compound CC(P(O)(O)=O)S(C[C@H]([C@H]([C@H]1O)O)O[C@H]1[n](c1n2)ncc1c(NC1CCCC1)nc2Cl)(=O)=O MAELJKQPTFAWLB-JQGYAOAWSA-N 0.000 description 1
- UUPOGTFPUWJTSD-MEUKVILTSA-N CC(P(O)(O)=O)S(C[C@H]([C@H]([C@H]1O)O)O[C@H]1[n](c1n2)nnc1c(NC1CCCC1)nc2Cl)(=O)=O Chemical compound CC(P(O)(O)=O)S(C[C@H]([C@H]([C@H]1O)O)O[C@H]1[n](c1n2)nnc1c(NC1CCCC1)nc2Cl)(=O)=O UUPOGTFPUWJTSD-MEUKVILTSA-N 0.000 description 1
- PXRYACWKRBJVCK-UHFFFAOYSA-N CCC(C)CN(C=C)C=C Chemical compound CCC(C)CN(C=C)C=C PXRYACWKRBJVCK-UHFFFAOYSA-N 0.000 description 1
- KBRSXBSFPOYXDI-UHFFFAOYSA-N CCOP(C(C)(CO)OCC(CC1OC(C)(C)O)OC1[n]1ncc2c(N(C3CCCC3)C(OC(C)(C)C)=O)nc(CCCO)nc12)=O Chemical compound CCOP(C(C)(CO)OCC(CC1OC(C)(C)O)OC1[n]1ncc2c(N(C3CCCC3)C(OC(C)(C)C)=O)nc(CCCO)nc12)=O KBRSXBSFPOYXDI-UHFFFAOYSA-N 0.000 description 1
- KYUIADQBIVUACQ-GKUKONBPSA-N CCOP(C(C)OC[C@H]([C@H]1OC(C)(C)O[C@H]11)O[C@H]1[n](c1n2)ncc1c(N(C1CCCC1)C(OC(C)(C)C)=O)nc2Cl)([O](C)CC)=O Chemical compound CCOP(C(C)OC[C@H]([C@H]1OC(C)(C)O[C@H]11)O[C@H]1[n](c1n2)ncc1c(N(C1CCCC1)C(OC(C)(C)C)=O)nc2Cl)([O](C)CC)=O KYUIADQBIVUACQ-GKUKONBPSA-N 0.000 description 1
- YZNRTQKCCPBGNV-LMPWSLQOSA-N CCOP([C@@H](CO)OC[C@H]([C@H]1OC(C)(C)O[C@H]11)O[C@H]1[n](c1n2)ncc1c(N(C1CCCC1)C(OC(C)(C)C)=O)nc2Cl)(OCC)=O Chemical compound CCOP([C@@H](CO)OC[C@H]([C@H]1OC(C)(C)O[C@H]11)O[C@H]1[n](c1n2)ncc1c(N(C1CCCC1)C(OC(C)(C)C)=O)nc2Cl)(OCC)=O YZNRTQKCCPBGNV-LMPWSLQOSA-N 0.000 description 1
- YZNRTQKCCPBGNV-ANOZEODCSA-N CCOP([C@H](CO)OC[C@H]([C@H]1OC(C)(C)O[C@H]11)O[C@H]1[n](c1n2)ncc1c(N(C1CCCC1)C(OC(C)(C)C)=O)nc2Cl)(OCC)=O Chemical compound CCOP([C@H](CO)OC[C@H]([C@H]1OC(C)(C)O[C@H]11)O[C@H]1[n](c1n2)ncc1c(N(C1CCCC1)C(OC(C)(C)C)=O)nc2Cl)(OCC)=O YZNRTQKCCPBGNV-ANOZEODCSA-N 0.000 description 1
- KJQOGVOBYZVJLI-ATNYBXOESA-N COCC(COC)(OC[C@H]([C@H]([C@H]1O)O)O[C@H]1[n](c1n2)ncc1c(NC1CCCC1)nc2Cl)P(O)(O)=O Chemical compound COCC(COC)(OC[C@H]([C@H]([C@H]1O)O)O[C@H]1[n](c1n2)ncc1c(NC1CCCC1)nc2Cl)P(O)(O)=O KJQOGVOBYZVJLI-ATNYBXOESA-N 0.000 description 1
- XEAAZMKJGPTWEZ-BVGIBNHUSA-N N#CC(OC[C@H]([C@H]([C@H]1O)O)O[C@H]1[n](c1n2)ncc1c(NC1CCCC1)nc2Cl)P(O)(O)=O Chemical compound N#CC(OC[C@H]([C@H]([C@H]1O)O)O[C@H]1[n](c1n2)ncc1c(NC1CCCC1)nc2Cl)P(O)(O)=O XEAAZMKJGPTWEZ-BVGIBNHUSA-N 0.000 description 1
- DMXMFPHJMRWKEA-WWRHJZOGSA-N OC[C@H](OC[C@H]([C@H]([C@H]1O)O)O[C@H]1[n](c1n2)ncc1c(NC1CCCC1)nc2Cl)P(O)(O)=O Chemical compound OC[C@H](OC[C@H]([C@H]([C@H]1O)O)O[C@H]1[n](c1n2)ncc1c(NC1CCCC1)nc2Cl)P(O)(O)=O DMXMFPHJMRWKEA-WWRHJZOGSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862664841P | 2018-04-30 | 2018-04-30 | |
| US62/664,841 | 2018-04-30 | ||
| US201862737647P | 2018-09-27 | 2018-09-27 | |
| US62/737,647 | 2018-09-27 | ||
| US201862757714P | 2018-11-08 | 2018-11-08 | |
| US62/757,714 | 2018-11-08 | ||
| US201862777697P | 2018-12-10 | 2018-12-10 | |
| US62/777,697 | 2018-12-10 | ||
| US201962810790P | 2019-02-26 | 2019-02-26 | |
| US62/810,790 | 2019-02-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202014182A true TW202014182A (zh) | 2020-04-16 |
Family
ID=68386646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW108115143A TW202014182A (zh) | 2018-04-30 | 2019-04-30 | Cd73抑制劑 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US11325938B2 (https=) |
| EP (2) | EP3787635B1 (https=) |
| JP (2) | JP7489323B2 (https=) |
| KR (1) | KR20210018255A (https=) |
| CN (2) | CN112423764A (https=) |
| AU (1) | AU2019261976B2 (https=) |
| BR (1) | BR112020022068A2 (https=) |
| CA (1) | CA3098493A1 (https=) |
| IL (1) | IL304348B2 (https=) |
| MX (2) | MX2020011542A (https=) |
| SG (1) | SG11202010790XA (https=) |
| TW (1) | TW202014182A (https=) |
| WO (1) | WO2019213174A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018208980A1 (en) | 2017-05-10 | 2018-11-15 | Oric Pharmaceuticals, Inc. | Cd73 inhibitors |
| US11377469B2 (en) | 2017-11-03 | 2022-07-05 | Oric Pharmaceuticals, Inc. | CD73 inhibitors |
| CN112423764A (zh) | 2018-04-30 | 2021-02-26 | 欧瑞克制药公司 | Cd73抑制剂 |
| EP3810109B1 (en) * | 2018-05-31 | 2024-08-07 | Peloton Therapeutics, Inc. | Compounds and compositions for inhibiting cd73 |
| AU2019288495B2 (en) | 2018-06-21 | 2024-02-08 | Antengene Therapeutics Limited | Ectonucleotidase inhibitors and methods of use thereof |
| AU2020256166A1 (en) | 2019-04-02 | 2021-10-14 | Aligos Therapeutics, Inc. | Compounds targeting PRMT5 |
| US12544391B2 (en) | 2019-07-16 | 2026-02-10 | Oric Pharmaceuticals, Inc. | CD73 inhibitors |
| HUE072504T2 (hu) | 2019-10-30 | 2025-11-28 | Oric Pharmaceuticals Inc | CD73-inhibitorok |
| EP4251633A4 (en) * | 2020-11-25 | 2024-09-25 | Risen (Suzhou) Pharma Tech Co., Ltd. | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF |
| WO2022237747A1 (zh) | 2021-05-11 | 2022-11-17 | 四川海思科制药有限公司 | 小分子cd73拮抗剂及其用途 |
| US20240140979A1 (en) * | 2022-10-03 | 2024-05-02 | Teon Therapeutics, Inc. | Heterocyclic inhibitors of cd73 for treatment of disease |
| WO2024076873A1 (en) * | 2022-10-03 | 2024-04-11 | Teon Therapeutics, Inc. | Heterocyclic inhibitors of cd73 for treatment of disease |
| CN116217644B (zh) * | 2023-04-24 | 2023-08-08 | 南京颐媛生物医学研究院有限公司 | 抗冠状病毒核糖核苷类化合物及其制备方法和应用 |
| WO2025162964A1 (en) | 2024-01-30 | 2025-08-07 | Institut National de la Santé et de la Recherche Médicale | Methods for the treatment of endometriosis |
| WO2025233264A1 (en) | 2024-05-07 | 2025-11-13 | Innate Pharma | Use of cd73 blocking agents in combination with anti-cd20 x cd3 t cell engagers |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0477454A1 (en) * | 1990-09-28 | 1992-04-01 | Merrell Dow Pharmaceuticals Inc. | Novel phosphonate derivatives of certain nucleosides |
| WO2002048165A2 (en) | 2000-12-15 | 2002-06-20 | Pharmasset Ltd. | Antiviral agents for treatment of flaviviridae infections |
| US20040229839A1 (en) * | 2003-05-14 | 2004-11-18 | Biocryst Pharmaceuticals, Inc. | Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases |
| WO2005020885A2 (en) | 2003-05-21 | 2005-03-10 | Isis Pharmaceuticals, Inc. | Compositions and methods for the treatment of severe acute respiratory syndrome (sars) |
| WO2007139946A2 (en) | 2006-05-25 | 2007-12-06 | University Of Tennessee Research Foundation | Gpcr ligands identified by computational modeling |
| DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
| WO2009127230A1 (en) | 2008-04-16 | 2009-10-22 | Curevac Gmbh | MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION |
| US20090274686A1 (en) * | 2008-05-02 | 2009-11-05 | Yat Sun Or | Nucleoside phosphonate derivatives |
| WO2015164573A1 (en) * | 2014-04-25 | 2015-10-29 | Vitae Pharmaceuticals, Inc. | Purine derivatives as cd73 inhibitors for the treatment of cancer |
| CN104530166B (zh) | 2014-12-04 | 2016-08-24 | 陕西汉江药业集团股份有限公司 | 选择性还原4,6-共轭双烯-3-酮甾体化合物的方法 |
| WO2017098421A1 (en) * | 2015-12-08 | 2017-06-15 | Glaxosmithkline Intellectual Property Development Limited | Benzothiadiazine compounds |
| HUE063388T2 (hu) * | 2016-01-08 | 2024-01-28 | Arcus Biosciences Inc | Ekto-5'-nukleotidáz modulátorok és ezek alkalmazása |
| TWI767937B (zh) * | 2016-09-09 | 2022-06-21 | 美商卡利泰拉生物科技公司 | 外核苷酸酶抑制劑及其使用方法 |
| CN110049767B (zh) * | 2016-10-03 | 2023-04-04 | 艾库斯生物科学有限公司 | 腺苷5′-核苷酸酶的抑制剂 |
| EP3541396A4 (en) | 2016-11-18 | 2020-07-22 | Arcus Biosciences, Inc. | CD73-MEDIATED IMMUNOSUPPRESSION INHIBITORS |
| JP7138351B2 (ja) | 2016-12-22 | 2022-09-16 | キャリセラ バイオサイエンシーズ， インコーポレイテッド | エクトヌクレオチダーゼ阻害剤およびその使用方法 |
| US20200115404A1 (en) * | 2017-03-31 | 2020-04-16 | Peloton Therapeutics, Inc. | Cd73 inhibitors and uses thereof |
| WO2018208727A1 (en) | 2017-05-08 | 2018-11-15 | Eternity Bioscience Inc. | Nucleoside and nucleotide analogues as cd73 inhibitors and therapeutic uses thereof |
| WO2018208980A1 (en) | 2017-05-10 | 2018-11-15 | Oric Pharmaceuticals, Inc. | Cd73 inhibitors |
| US11377469B2 (en) | 2017-11-03 | 2022-07-05 | Oric Pharmaceuticals, Inc. | CD73 inhibitors |
| CN112423764A (zh) | 2018-04-30 | 2021-02-26 | 欧瑞克制药公司 | Cd73抑制剂 |
| EP3810109B1 (en) | 2018-05-31 | 2024-08-07 | Peloton Therapeutics, Inc. | Compounds and compositions for inhibiting cd73 |
| AU2019288495B2 (en) | 2018-06-21 | 2024-02-08 | Antengene Therapeutics Limited | Ectonucleotidase inhibitors and methods of use thereof |
| EP3843714B1 (en) | 2018-08-27 | 2025-11-12 | Arcus Biosciences, Inc. | Cd73 inhibitors |
| KR20220024629A (ko) | 2019-06-20 | 2022-03-03 | 칼리테라 바이오사이언시즈, 인코포레이티드 | 엑토뉴클레오티다제 억제제 및 이의 사용 방법 |
| US12544391B2 (en) | 2019-07-16 | 2026-02-10 | Oric Pharmaceuticals, Inc. | CD73 inhibitors |
| HUE072504T2 (hu) | 2019-10-30 | 2025-11-28 | Oric Pharmaceuticals Inc | CD73-inhibitorok |
-
2019
- 2019-04-30 CN CN201980044455.4A patent/CN112423764A/zh active Pending
- 2019-04-30 BR BR112020022068-0A patent/BR112020022068A2/pt not_active Application Discontinuation
- 2019-04-30 EP EP19796584.1A patent/EP3787635B1/en active Active
- 2019-04-30 CN CN202510454173.9A patent/CN120699076A/zh active Pending
- 2019-04-30 TW TW108115143A patent/TW202014182A/zh unknown
- 2019-04-30 EP EP25202200.9A patent/EP4674481A3/en active Pending
- 2019-04-30 MX MX2020011542A patent/MX2020011542A/es unknown
- 2019-04-30 KR KR1020207034512A patent/KR20210018255A/ko not_active Ceased
- 2019-04-30 AU AU2019261976A patent/AU2019261976B2/en active Active
- 2019-04-30 IL IL304348A patent/IL304348B2/en unknown
- 2019-04-30 CA CA3098493A patent/CA3098493A1/en active Pending
- 2019-04-30 SG SG11202010790XA patent/SG11202010790XA/en unknown
- 2019-04-30 JP JP2020560361A patent/JP7489323B2/ja active Active
- 2019-04-30 WO PCT/US2019/030068 patent/WO2019213174A1/en not_active Ceased
-
2020
- 2020-10-23 US US17/078,567 patent/US11325938B2/en active Active
- 2020-10-29 MX MX2023002507A patent/MX2023002507A/es unknown
-
2022
- 2022-03-17 US US17/697,318 patent/US11807658B2/en active Active
-
2023
- 2023-09-28 US US18/476,763 patent/US20240124512A1/en not_active Abandoned
-
2024
- 2024-05-13 JP JP2024078186A patent/JP2024112864A/ja active Pending
-
2025
- 2025-06-11 US US19/234,635 patent/US20250368677A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3098493A1 (en) | 2019-11-07 |
| US11325938B2 (en) | 2022-05-10 |
| WO2019213174A1 (en) | 2019-11-07 |
| MX2023002507A (es) | 2023-03-13 |
| BR112020022068A2 (pt) | 2021-04-20 |
| US20240124512A1 (en) | 2024-04-18 |
| MX2020011542A (es) | 2020-11-24 |
| CN112423764A (zh) | 2021-02-26 |
| JP2024112864A (ja) | 2024-08-21 |
| US20250368677A1 (en) | 2025-12-04 |
| IL304348B2 (en) | 2024-08-01 |
| EP4674481A3 (en) | 2026-03-04 |
| EP4674481A2 (en) | 2026-01-07 |
| SG11202010790XA (en) | 2020-11-27 |
| CN120699076A (zh) | 2025-09-26 |
| IL304348B1 (en) | 2024-04-01 |
| KR20210018255A (ko) | 2021-02-17 |
| US20220220147A1 (en) | 2022-07-14 |
| EP3787635A4 (en) | 2022-03-02 |
| EP3787635B1 (en) | 2025-09-17 |
| US20210047359A1 (en) | 2021-02-18 |
| AU2019261976B2 (en) | 2025-01-23 |
| US11807658B2 (en) | 2023-11-07 |
| JP7489323B2 (ja) | 2024-05-23 |
| AU2019261976A1 (en) | 2020-12-03 |
| JP2021522280A (ja) | 2021-08-30 |
| EP3787635A1 (en) | 2021-03-10 |
| IL304348A (en) | 2023-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW202014182A (zh) | Cd73抑制劑 | |
| AU2020375914B2 (en) | CD73 inhibitors | |
| US11377469B2 (en) | CD73 inhibitors | |
| HK40047148A (en) | Cd73 inhibitors | |
| HK40047148B (en) | Cd73 inhibitors | |
| EA043919B1 (ru) | Ингибиторы cd73 | |
| HK40081385B (en) | Cd73 inhibitors | |
| HK40081385A (en) | Cd73 inhibitors |